Servier, an independent international pharmaceutical group governed by a foundation, announces that it has completed the acquisition of the muscular dystrophy business of Edgewise Therapeutics Inc. (Nasdaq: EWTX), for up to $2.65 billion, including upfront payment of $1.55 billion as well as up to $1.1 billion in regulatory and commercial milestone payments. The acquisition significantly advances Servier’s rare neurology pipeline with a late-stage asset, sevasemten, currently being investigated in a pivotal cohort in Becker muscular dystrophy (BMD), and in phase 2 in Duchenne muscular dystrophy (DMD). It also provides Servier with additional capabilities by integrating Edgewise Therapeutics’ expertise to advance the development of sevasemten.
Read the full article: Servier Completes the Acquisition of Edgewise Therapeutics’ Muscular Dystrophy Business //
Source: https://www.prnewswire.com/news-releases/servier-completes-the-acquisition-of-edgewise-therapeutics-muscular-dystrophy-business-302822911.html